ReviewDrug design, development and therapy2025
Emerging Strategies for Bioactive Agent-Loaded Xenogeneic Bone Scaffolds in Regenerative Medicine: A Comprehensive Review.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Apple-Derived Vesicles Orchestrate Bone Regeneration:International journal of molecular sciences · 2026Article
- Design and Fabrication of Biomimetic Gradient Bone Tissue Engineering Scaffolds: Evolution from Single-Gradient to Multi-Gradient.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The escalating global burden of an aging population and the rising incidence of secondary traumatic injuries have precipitated a mounting worldwide demand for bone grafts. However, autologous bone transplantation-the prevailing clinical "gold standard"-remains insufficient to meet this growing clinical need. Notably, rapid advancements in bone tissue engineering (BTE) have yielded diverse bone graft substitutes designed to recapitulate the three essential characteristics of bone tissue: osteoconductivity, osteoinductivity, and osteogenic potential. Within this domain, core scaffolds functioning as carriers for bioactive agents represent a highly promising strategy for treating bone defects. This review focuses on the design and fabrication of optimal xenogeneic bone scaffolds. It systematically examines commonly loaded bioactive components, including bone morphogenetic proteins (BMPs), platelet-rich plasma (PRP), natural products, active ingredients derived from traditional Chinese medicine ingredients (TCMs), and exosomes. The advantages and limitations inherent to these agents are critically analyzed. Furthermore, the review addresses current challenges and explores future research directions in bone scaffold engineering. By advancing multimodal strategies for modulating the delivery of bioactive agents, we aim to provide more effective therapeutic solutions for patients with critical bone defects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.